LAK细胞/IL-2联合放射免疫治疗晚期肿瘤的临床研究

The Study on the Treatment of the Malignant Tumor of Digestive Tract with ¹³¹I一CL₃ in Tratumoral Injection Alone or Combined with LAK/IL-2 Intravenous Injection

摘要: 观察了72例接受不同方法治疗的晚期消化道恶性肿瘤患者愈后及γ显像情况,患者随机分为3组,第一组21例单独应用¹³¹I标记的抗结肠癌单克隆抗体CL₃(简称¹³¹I-CL₃)局部多点注射治疗;第二组33例接受LAK细胞/IL-2静脉注射治疗;第三组18例接受LAK细胞/IL-2联合¹³¹I-CL₃肿瘤局部多点注射治疗。发现:(1)LAK细胞/IL-2和¹³¹I-CL₃联合应用组,肿瘤局部核素标记抗体浓聚大于¹³¹I-CL₃组。(2)联合应用LAK细胞/IL-2及¹³¹I-CL₃治疗组的有效率(CR+PR,50%)明显高于¹³¹I-CL₃治疗组(238%)及LAK细胞/IL-2治疗组(121%)。说明LAK细胞/IL-2联合应用后可增强放免显像及放免治疗的效果。

Abstract: Purpose:To explore the affection of the LAK/IL-2 intavenous injection(LAK/IL-2 IV) to the therapeutic cfficay of the radioimmunothcrapy .Method:There were 72 patients with malignant tumor of digestive tract in this study, 21 patients recepting ¹³¹I-CL₃ intratumoral injection alone(¹³¹I一CL₃ IT)，33 patients recepting LAK/IL一2 IV alone, and 18 patient recepting ¹³¹I一IL₃ IT conbined with LAK/IL一2IV. Result:The therapeutic efficay of ¹³¹I一CL₃ IT alone or LAK/IL一2 IV alone. Conclusion:LAK/IL-2 IV can enhance the therapeutic efFicay of raclicoimmunotherapy.